---
title: "Weekly Recap | Beigene +2.32%, Tevimbra combination survival data lands"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302953647.md"
description: "Beigene (ONC) gained 2.32% this week to close at $377.63, up from $369.06 the previous Friday. The S&P 500 fell 0.47% over the same stretch, leaving the stock about 2.79 percentage points ahead of the benchmark. The week opened weakly at $371.53 and printed an intraweek low of $368.51 on Monday, then rallied hard on Tuesday and Wednesday. Wednesday marked the high at $388.66 before easing, and Friday saw a pullback from an open of $384.40 to an intraday low of $372."
datetime: "2026-10-24T06:49:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302953647.md)
  - [en](https://longbridge.com/en/news/302953647.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302953647.md)
generator: "portal-rs"
---

# Weekly Recap | Beigene +2.32%, Tevimbra combination survival data lands

## The Week

Beigene (ONC) gained 2.32% this week to close at $377.63, up from $369.06 the previous Friday. The S&P 500 fell 0.47% over the same stretch, leaving the stock about 2.79 percentage points ahead of the benchmark. The week opened weakly at $371.53 and printed an intraweek low of $368.51 on Monday, then rallied hard on Tuesday and Wednesday. Wednesday marked the high at $388.66 before easing, and Friday saw a pullback from an open of $384.40 to an intraday low of $372.65, finishing at $377.63.

## Key Events

Clinical news around gastric and gastroesophageal cancers dominated the week. On Friday, BeOne Medicines said its Tevimbra combination extended median survival to 27 months in a gastroesophageal cancer trial, and it reported sustained overall survival benefit from a Phase 3 HER2+ gastric cancer trial. Earlier in the week, the company said it would present Phase 1 liver cancer drug data at ESMO 2026. Beigene also confirmed it will report third-quarter 2026 results before the open on 5 November; the market is looking for EPS of $1.9058 and revenue of $1.758 billion. The shares dipped 8.69% pre-market on Tuesday, hit a 52-week high on Wednesday, and slipped again on Friday.

## Analyst Ratings

Of 27 institutions covering the stock, 19 rate it buy, 7 rate it overweight, and 1 rates it hold, with no underweight or sell ratings. The consensus rating is strong buy, and the consensus target price of $436.46 implies about 15.58% upside from the current price. Targets range from $370 to $528, so the spread is wide. Beigene ranks 11th within the biotech industry group, where 511 names are covered.

## The Week Ahead

A heavy macro slate starts with Dallas Fed manufacturing activity on Monday. Tuesday brings durable goods orders, FHFA house prices, Case Shiller home-price data, new home sales, the Richmond Fed composite, and consumer confidence. On the company side, third-quarter 2026 results land before the open on 5 November, with estimates at EPS of $1.9058 and revenue of $1.758 billion. The question is whether this week’s clinical momentum shows up in the operating numbers.

## In Short

This week paired positive clinical data with a mostly upbeat rating picture: the Tevimbra survival read strengthened the pipeline narrative, the consensus rating is strong buy, and the target sits above spot. At the same time, the stock pulled back after touching a 52-week high, and the latest session’s fund-flow snapshot showed small-lot net buying alongside a split between medium and large lots. The next check is whether third-quarter results can carry the momentum, and how valuation and money flows converge from here.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)

## Related News & Research

- [BeOne Medicines’ Tevimbra Combination Extends Median Survival to 27 Months in Gastroesophageal Cancer Trial](https://longbridge.com/en/news/302895730.md)
- [BeOne stock breaks out with visions of 177% earnings growth. This telltale clue bodes well.](https://longbridge.com/en/news/302773305.md)
- [BeOne Reports 36% Response Rate for BGB-B2033 in Phase 1 Liver Cancer Trial](https://longbridge.com/en/news/302957977.md)
- [BeOne Medicines Ltd. Unveils ESMO Data, Targets HCC Registration in 2026](https://longbridge.com/en/news/302958159.md)
- [BeOne Medicines to Present Phase 1 Liver Cancer Drug Data at ESMO 2026](https://longbridge.com/en/news/302270315.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**